GSK, Flagship Commit $150M Upfront for Initial Development of Respiratory, Immunology Programs

Flagship Pioneering and its portfolio companies are in line to receive up to $720 million in milestones for each of the 10 programs that GSK could option, according to Monday’s announcement.